Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma.
antibody drug conjugates
monoclonal antibodies
multiple myeloma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Mar 2021
29 Mar 2021
Historique:
received:
24
02
2021
revised:
22
03
2021
accepted:
27
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Multiple myeloma is the second most common hematologic malignancy. Current treatment strategies are mainly based on immunomodulatory drugs, proteasome inhibitors or combination of both. Novel agents added to these backbone treatments represent a promising strategy in treatment of newly diagnosed as well as relapsed and refractory multiple myeloma patients. In this respect, the incorporation of monoclonal antibodies into standard-of-care regimens markedly improved prognosis of myeloma patients during the last years. More specifically, monoclonal anti-CD38 antibodies, daratumumab and isatuximab, have been implemented into treatment strategies from first-line treatment to refractory disease. In addition, the monoclonal anti-SLAM-F7 antibody elotuzumab in combination with immunomodulatory drugs has improved the clinical outcomes of patients with relapsed/refractory disease. Belantamab mafodotin is the first approved antibody drug conjugate directed against B cell maturation antigen and is currently used as a monotherapy for patients with advanced disease. This review focuses on clinical efficacy and safety of monoclonal antibodies as well as antibody drug conjugates in multiple myeloma.
Identifiants
pubmed: 33805481
pii: cancers13071571
doi: 10.3390/cancers13071571
pmc: PMC8037134
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : MH CZ - DRO (UHHK, 00179906)
Organisme : Univerzita Karlova v Praze
ID : PROGRES Q40/8
Références
Proc Natl Acad Sci U S A. 1980 Mar;77(3):1588-92
pubmed: 6966400
Nat Med. 2001 Nov;7(11):1209-16
pubmed: 11689885
Blood. 2014 May 15;123(20):3128-38
pubmed: 24569262
Clin Cancer Res. 2015 Jun 15;21(12):2802-10
pubmed: 25398450
Blood. 2016 Jun 9;127(23):2833-40
pubmed: 27091875
J Clin Oncol. 2010 May 1;28(13):2259-66
pubmed: 20368561
Blood Adv. 2021 Dec 14;5(23):5128-5139
pubmed: 34625791
J Immunol. 2011 Feb 1;186(3):1840-8
pubmed: 21187443
PLoS One. 2019 Feb 13;14(2):e0211927
pubmed: 30759167
Blood. 2018 Jan 25;131(4):464-467
pubmed: 29167176
Blood Lymphat Cancer. 2014 Jun;2014(4):15-27
pubmed: 26005365
N Engl J Med. 2018 Feb 8;378(6):518-528
pubmed: 29231133
Mol Cancer Ther. 2018 Jul;17(7):1454-1463
pubmed: 29654064
Nat Immunol. 2009 Mar;10(3):297-305
pubmed: 19151721
Mol Med. 2016 Dec;22:694-704
pubmed: 27761584
Transfusion. 2015 Jun;55(6 Pt 2):1555-62
pubmed: 25988285
Leukemia. 2021 Jan;35(1):201-214
pubmed: 32350373
Cancer. 2019 Sep 1;125(17):2991-3000
pubmed: 31090928
Haematologica. 2021 Apr 01;106(4):1182-1187
pubmed: 32586908
Physiol Rev. 2008 Jul;88(3):841-86
pubmed: 18626062
Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):44-51
pubmed: 29054515
Cancer Med. 2020 Mar;9(6):2077-2084
pubmed: 31991058
Leukemia. 2021 Jan;35(1):31-44
pubmed: 32814840
Blood. 2017 Jun 1;129(22):3033-3037
pubmed: 28373263
MAbs. 2015;7(2):311-21
pubmed: 25760767
Expert Opin Biol Ther. 2021 Jul;21(7):889-901
pubmed: 32729730
Leukemia. 2021 Feb;35(2):562-572
pubmed: 32444867
Blood. 2012 Jul 19;120(3):552-9
pubmed: 22184404
Front Immunol. 2018 Sep 20;9:2134
pubmed: 30294326
Blood. 2016 Jul 7;128(1):37-44
pubmed: 27216216
Clin Cancer Res. 2014 Sep 1;20(17):4574-83
pubmed: 24987056
Leukemia. 2018 Nov;32(11):2495-2518
pubmed: 29679038
Oncotarget. 2018 Oct 5;9(78):34784-34793
pubmed: 30410677
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
Immunity. 2004 Mar;20(3):279-91
pubmed: 15030772
Lancet. 2016 Apr 9;387(10027):1551-1560
pubmed: 26778538
Haematologica. 2022 Jun 01;107(6):1397-1409
pubmed: 34647444
Front Immunol. 2020 Aug 14;11:1771
pubmed: 32922390
Exp Hematol Oncol. 2018 Oct 16;7:27
pubmed: 30356940
Onco Targets Ther. 2016 Oct 05;9:6037-6048
pubmed: 27785050
Blood. 2015 Jul 2;126(1):50-60
pubmed: 26002964
Cells. 2019 Nov 27;8(12):
pubmed: 31783629
Front Cell Dev Biol. 2019 Apr 16;7:50
pubmed: 31041312
Br J Clin Pharmacol. 2020 Jul;86(7):1314-1325
pubmed: 32045493
Blood. 2021 Mar 4;137(9):1154-1165
pubmed: 33080623
Clin Cancer Res. 2008 May 1;14(9):2775-84
pubmed: 18451245
JAMA Oncol. 2020 Nov 01;6(11):1759-1765
pubmed: 32970151
Mol Cancer Res. 2020 Jan;18(1):3-19
pubmed: 31659006
Br J Haematol. 2018 Oct;183(1):60-67
pubmed: 30080247
Blood. 2020 Aug 20;136(8):936-945
pubmed: 32325490
Clin Chem Lab Med. 2016 Jun 1;54(6):1105-9
pubmed: 26812873
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S83-S94
pubmed: 29572070
Leuk Lymphoma. 2021 Jun;62(6):1510-1513
pubmed: 33491527
Lancet. 2019 Jul 6;394(10192):29-38
pubmed: 31171419
Blood. 2018 Jan 4;131(1):13-29
pubmed: 29118010
Br J Haematol. 2021 Mar;192(5):869-878
pubmed: 33216361
Leukemia. 2019 Sep;33(9):2266-2275
pubmed: 30858549
Cytometry A. 2019 Mar;95(3):279-289
pubmed: 30536810
Lancet. 2019 Dec 7;394(10214):2096-2107
pubmed: 31735560
Bioconjug Chem. 2006 Jan-Feb;17(1):114-24
pubmed: 16417259
Cancer Immunol Immunother. 2013 Dec;62(12):1841-9
pubmed: 24162108
Haematologica. 2018 Dec;103(12):2079-2087
pubmed: 30237264
Transfusion. 2016 Dec;56(12):2964-2972
pubmed: 27600566
Lancet Haematol. 2020 May;7(5):e381-e394
pubmed: 32171061
N Engl J Med. 2019 May 30;380(22):2104-2115
pubmed: 31141632
Br J Haematol. 2021 May;193(4):705-722
pubmed: 33216972
Lancet Haematol. 2020 Jun;7(6):e447-e455
pubmed: 32470437
J Exp Med. 2014 Apr 7;211(4):727-42
pubmed: 24687958
N Engl J Med. 2015 Sep 24;373(13):1207-19
pubmed: 26308596
Blood Adv. 2022 Aug 9;6(15):4506-4515
pubmed: 35594559
Leukemia. 2020 Jan;34(1):180-195
pubmed: 31358854
Clin Cancer Res. 2019 May 15;25(10):3176-3187
pubmed: 30692097
Eur J Haematol. 2020 May;104(5):420-426
pubmed: 31880853
Hemasphere. 2021 Feb 17;5(3):e547
pubmed: 33623886
Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):372-380
pubmed: 30930134
Expert Opin Pharmacother. 2021 Jun;22(9):1203-1215
pubmed: 33524268
Haematologica. 2011 Feb;96(2):284-90
pubmed: 21109694
J Oncol Pract. 2018 Jul;14(7):414-422
pubmed: 29996069
J Oncol Pharm Pract. 2021 Jul;27(5):1080-1085
pubmed: 32865161
Blood Cancer J. 2020 Sep 4;10(9):91
pubmed: 32887873
Lancet. 2020 Jan 11;395(10218):132-141
pubmed: 31836199
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32661116
Ophthalmol Ther. 2020 Dec;9(4):889-911
pubmed: 32712806
Leukemia. 2021 Jan;35(1):255-258
pubmed: 32317775
N Engl J Med. 2015 Aug 13;373(7):621-31
pubmed: 26035255
Cancer Res. 2019 May 1;79(9):2285-2297
pubmed: 30622116
JAMA Oncol. 2020 Feb 1;6(2):293-294
pubmed: 31774462
Cancer Cell. 2009 Oct 6;16(4):309-23
pubmed: 19800576
Lancet Haematol. 2021 Jan;8(1):e45-e54
pubmed: 33357482
Lancet Oncol. 2020 Feb;21(2):207-221
pubmed: 31859245
Leuk Lymphoma. 2020 Mar;61(3):691-698
pubmed: 31739729
Lancet Oncol. 2018 Dec;19(12):1641-1653
pubmed: 30442502
Haematologica. 2020 Jan 31;105(2):468-477
pubmed: 31221782
Lancet Haematol. 2020 May;7(5):e370-e380
pubmed: 32213342
Clin Cancer Res. 2017 Dec 15;23(24):7498-7511
pubmed: 29025767
Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):29-34
pubmed: 30340993
N Engl J Med. 2018 Nov 8;379(19):1811-1822
pubmed: 30403938
Haematologica. 2018 Dec;103(12):2088-2096
pubmed: 30237262
N Engl J Med. 2016 Oct 6;375(14):1319-1331
pubmed: 27705267
Blood. 2016 Aug 18;128(7):959-70
pubmed: 27307294
J Appl Lab Med. 2019 Mar;3(5):857-863
pubmed: 31639760
BMC Cancer. 2019 May 28;19(1):504
pubmed: 31138244
J Clin Oncol. 2015 Sep 10;33(26):2863-9
pubmed: 26240224
Med Res Rev. 2012 Mar;32(2):254-93
pubmed: 20544978
Leukemia. 2020 Aug;34(8):2000-2011
pubmed: 32444866
Leukemia. 2020 Jul;34(7):1875-1884
pubmed: 32001798
Lancet. 2020 Jul 18;396(10245):186-197
pubmed: 32682484
Cancers (Basel). 2020 Jul 04;12(7):
pubmed: 32635428
Blood Cancer J. 2019 Mar 20;9(4):37
pubmed: 30894515
Blood. 2016 Jul 21;128(3):384-94
pubmed: 27222480